[Ip-health] New York Times: Drug Goes From $13.50 a Tablet to $750, Overnight
thiru at keionline.org
Sun Sep 20 23:43:31 PDT 2015
Drug Goes From $13.50 a Tablet to $750, Overnight
By ANDREW POLLACK
SEPT. 20, 2015
Specialists in infectious disease are protesting a gigantic overnight
increase in the price of a 62-year-old drug that is the standard of care
for treating a life-threatening parasitic infection.
The drug, called Daraprim, was acquired in August by Turing
Pharmaceuticals, a start-up run by a former hedge fund manager. Turing
immediately raised the price to $750 a tablet from $13.50, bringing the
annual cost of treatment for some patients to hundreds of thousands of
“What is it that they are doing differently that has led to this dramatic
increase?” said Dr. Judith Aberg, the chief of the division of infectious
diseases at the Icahn School of Medicine at Mount Sinai. She said the price
increase could force hospitals to use “alternative therapies that may not
have the same efficacy.”
Turing’s price increase is not an isolated example. While most of the
attention on pharmaceutical prices has been on new drugs for diseases like
cancer, hepatitis C and high cholesterol, there is also growing concern
about huge price increases on older drugs, some of them generic, that have
long been mainstays of treatment.
Although some price increases have been caused by shortages, others have
resulted from a business strategy of buying old neglected drugs and turning
them into high-priced “specialty drugs.”
Cycloserine, a drug used to treat dangerous multidrug-resistant
tuberculosis, was just increased in price to $10,800 for 30 pills from $500
after its acquisition by Rodelis Therapeutics. Scott Spencer, general
manager of Rodelis, said the company needed to invest to make sure the
supply of the drug remained reliable. He said the company provided the drug
free to certain needy patients.
In August, two members of Congress investigating generic drug price
increases wrote to Valeant Pharmaceuticals after that company acquired two
heart drugs, Isuprel and Nitropress, from Marathon Pharmaceuticals and
promptly raised their prices by 525 percent and 212 percent respectively.
Marathon had acquired the drugs from another company in 2013 and had
quintupled their prices, according to the lawmakers, SenatorBernie Sanders,
the Vermont independent who is seeking the Democratic nomination for
president, and Representative Elijah E. Cummings, Democrat of Maryland.
Doxycycline, an antibiotic, went from $20 a bottle in October 2013 to
$1,849 by April 2014, according to the two lawmakers.
The Infectious Diseases Society of America and the HIV Medicine Association
sent a joint letter to Turing earlier this month calling the price increase
for Daraprim “unjustifiable for the medically vulnerable patient
population” and “unsustainable for the health care system.” An organization
representing the directors of state AIDS programs has also been looking
into the price increase, according to doctors and patient advocates.
Daraprim, known generically as pyrimethamine, is used mainly to
treattoxoplasmosis, a parasite infection that can cause serious or even
life-threatening problems for babies born to women who become infected
during pregnancy, and also for people with compromised immune systems, like
AIDS patients and certain cancer patients.
Martin Shkreli, the founder and chief executive of Turing, said that the
drug is so rarely used that the impact on the health system would be
minuscule and that Turing would use the money it earns to develop better
treatments for toxoplasmosis, with fewer side effects.
“This isn’t the greedy drug company trying to gouge patients, it is us
trying to stay in business,” Mr. Shkreli said. He said that many patients
use the drug for far less than a year and that the price was now more in
line with those of other drugs for rare diseases.
“This is still one of the smallest pharmaceutical products in the world,”
he said. “It really doesn’t make sense to get any criticism for this.”
This is not the first time the 32-year-old Mr. Shkreli, who has a
reputation for both brilliance and brashness, has been the center of
controversy. He started MSMB Capital, a hedge fund company, in his 20s and
drew attention for urging the Food and Drug Administration not to approve
certain drugs made by companies whose stock he was shorting.
In 2011, Mr. Shkreli started Retrophin, which also acquired old neglected
drugs and sharply raised their prices. Retrophin’s board fired Mr. Shkreli
a year ago. Last month, it filed a complaint in Federal District Court in
Manhattan, accusing him of using Retrophin as a personal piggy bank to pay
back angry investors in his hedge fund.
Mr. Shkreli has denied the accusations. He has filed for arbitration
against his old company, which he says owes him at least $25 million in
severance. “They are sort of concocting this wild and crazy and unlikely
story to swindle me out of the money,” he said.
Daraprim, which is also used to treat malaria, was approved by the F.D.A.
in 1953 and has long been made by GlaxoSmithKline. Glaxo sold United States
marketing rights to CorePharma in 2010. Last year, Impax Laboratories
agreed to buy Core and affiliated companies for $700 million. In August,
Impax sold Daraprim to Turing for $55 million, a deal announced the same
day Turing said it had raised $90 million from Mr. Shkreli and other
investors in its first round of financing.
Daraprim cost only about $1 a tablet several years ago, but the drug’s
price rose sharply after CorePharma acquired it. According to IMS Health,
which tracks prescriptions, sales of the drug jumped to $6.3 million in
2011 from $667,000 in 2010, even as prescriptions held steady at about
12,700. In 2014, after further price increases, sales were $9.9 million, as
the number of prescriptions shrank to 8,821. The figures do not include
inpatient use in hospitals.
Turing’s price increase could bring sales to tens or even hundreds of
millions of dollars a year if use remains constant. Medicaid and certain
hospitals will be able to get the drug inexpensively under federal rules
for discounts and rebates. But private insurers, Medicare and hospitalized
patients would have to pay an amount closer to the list price.
Some doctors questioned Turing’s claim that there was a need for better
drugs, saying the side effects, while potentially serious, could be managed.
“I certainly don’t think this is one of those diseases where we have been
clamoring for better therapies,” said Dr. Wendy Armstrong, professor of
infectious diseases at Emory University in Atlanta.
With the price now high, other companies could conceivably make generic
copies, since patents have long expired. One factor that could discourage
that option is that Daraprim’s distribution is now tightly controlled,
making it harder for generic companies to get the samples they need for the
The switch from drugstores to controlled distribution was made in June by
Impax, not by Turing. Still, controlled distribution was a strategy Mr.
Shkreli talked about at his previous company as a way to thwart generics.
Some hospitals say they now have trouble getting the drug. “We’ve not had
access to the drug for a few months,” said Dr. Armstrong, who also works at
Grady Memorial Hospital, a huge public treatment center in Atlanta that
serves many low-income patients.
But Dr. Rima McLeod, medical director of the toxoplasmosis center at the
University of Chicago, said that Turing had been good about delivering
drugs quickly to patients, sometimes without charge.
“They have jumped every time I’ve called,” she said. The situation, she
added, “seems workable” despite the price increase.
Daraprim is the standard first treatment for toxoplasmosis, in combination
with an antibiotic called sulfadiazine. There are alternative treatments,
but there is less data supporting their efficacy.
Dr. Aberg of Mount Sinai said some hospitals will now find Daraprim too
expensive to keep in stock, possibly resulting in treatment delays. She
said that Mount Sinai was continuing to use the drug, but each use now
required a special review.
“This seems to be all profit-driven for somebody,” Dr. Aberg said, “and I
just think it’s a very dangerous process.”
More information about the Ip-health